Hemostatic function in young subjects with central obesity: relationship with left ventricular function.

6533b7d5fe1ef96bd12653d2

RESEARCH PRODUCT

Hemostatic function in young subjects with central obesity: relationship with left ventricular function.

Giuseppe Licata S. Arnone Gino Avellone A. Ganguzza Corrao Salvatore Rosario Scaglione Tiziana Di Chiara

subject

Adult Blood Glucose Male medicine.medical_specialty Settore MED/09 - Medicina Interna Apolipoprotein B Endocrinology Diabetes and Metabolism medicine.medical_treatment Fibrinogen Ventricular Function Left Settore MED/15 - Malattie Del Sangue chemistry.chemical_compound Endocrinology Waist–hip ratio Internal medicine Fibrinolysis medicine Humans Insulin Obesity Hemostatic function Blood Coagulation Apolipoproteins A Triglycerides Apolipoproteins B Hemostasis biology business.industry Cholesterol Cholesterol HDL Fibrinogen Central obesity Hemostatic function left ventricular function Plasminogen Factor VII Settore MED/11 - Malattie Dell'Apparato Cardiovascolare Plasminogen Inactivators Endocrinology chemistry biology.protein Body Constitution Regression Analysis Female business Plasminogen activator medicine.drug Lipoprotein

description

This study was designed to evaluate coagulation and fibrinolysis activity and their relationship with left ventricular function in young obese subjects with central fat distribution. We assessed coagulation and fibrinolysis activity by evaluation of factor VII activity, fibrinogen and plasminogen, plasminogen activator inhibitor (PAI), and tissue plasminogen activator antigen basally (tPA1) and after venous occlusion (tPA2). These measures were evaluated in young (< 40 years) obese subjects with central fat distribution (n = 19) and in comparable lean subjects (n = 20). Blood glucose, triglycerides, total and high-density lipoprotein (HDL) cholesterol, apolipoprotein (apo) A1 and apo B, fasting immunoreactive insulin, and lipoprotein(a) levels were also measured by current methods. Left ventricular ejection fraction (LVEF) and peak filling rate (PFR) determined by radionuclide angiocardiography and left ventricular mass (LVM) and LVM indexed for body height (LVM/H) determined by echocardiographic study were calculated. Central obesity was evaluated by the waist to hip ratio (WHR) according to the criteria of the Italian Consensus Conference of Obesity. Factor VII (P < .001), fibrinogen (P < .001), plasminogen (P < .001), PAI activity (P < .001), tPA1 (P < .02), fasting blood glucose (P < .01), apo B (P < .02), and immunoreactive insulin (P < .01) were significantly higher in obese than in lean subjects. In contrast, HDL cholesterol (P < .01), tPA2 (P < .01), LVEF (P < .001), and PFR (P < .02) were significantly lower in obese than in lean subjects. In all subjects, WHR correlated directly with fibrinogen and inversely with tPA2; LVEF correlated inversely with tPA1, PAI, and fibrinogen; and PFR correlated inversely with factor VII activity. Multiple regression analysis indicated that WHR and PAI were independent predictors of LVEF. These results indicate that obese subjects with central fat distribution are characterized by a hypercoagulable state associated with a silent left ventricular dysfunction. Such alterations might be responsible for the higher cardiovascular risk in subjects with central obesity.

year	journal	country	edition	language
1995-11-01	Metabolism: clinical and experimental

10.1016/0026-0495(95)90140-x https://pubmed.ncbi.nlm.nih.gov/7476328